Sentences with phrase «early stage of breast cancer»

Plaintiff herself was diagnosed with an early stage of breast cancer in January 2000.

Our results provide supportive evidence of the important role of dietary exposures during a unique period in a woman's life in the earlier stage of breast carcinogenesis [the early stage of breast cancer development].

Also called pre-cancer, this is the earliest stage of breast cancer.

Not exact matches

Juno also has a few other compounds in early stages of development aimed at treating NHL, pediatric ALL, multiple myeloma, ovarian & breast cancer, AML, lung cancer, and more.

As part of her treatment, Lee underwent a double mastectomy for early stage breast cancer.

On average, between 2006 - 2010, only 66 % of the breast cancer cases in Erie County were diagnosed at an early stage, so we have a great deal of room for improvement.»

In her opinion, it remains essential to screen aggressively for breast cancer in hopes of catching the disease in an early, treatable stage.

The trial has also included 10 HER -2-negative breast cancer patients, all of them in early stages of the disease.

The researchers at 30 radiotherapy centres across the UK, led by The Institute of Cancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of comingCancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of comingCancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of comingcancer that was at a low risk of coming back.

While women with early stage breast cancer often are cured of their disease, they live with surgical consequences throughout survivorship.

Professor Arnie Purushotham, Cancer Research UK's senior clinical adviser, said: «One of the challenges when treating early stage breast cancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curinCancer Research UK's senior clinical adviser, said: «One of the challenges when treating early stage breast cancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curincancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curing her.

What are the challenges of detecting breast cancer in its early stages?

They found that after the extension of the upper age limit, the incidence of early stage breast cancer (stages 0, I and II) increased significantly from 260 cases per 100,000 women in 1995 to up to 382 cases per 100,000 women in 2011.

An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1 % increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage.

Instead, researchers told the European Breast Cancer Conference that their findings suggest that extending screening programs to older women results in a large proportion of women being over-treated, and at risk from the harmful effects of such treatment, because these women were more likely to die from other causes than from any tumors detected in the early stages of growth.

Dr Gerrit - Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology research group at Leiden University Medical Centre (Leiden, The Netherlands), said: «For a screening program to be effective, one would expect that the incidence of early stage breast cancer would increase while the incidence of advanced stage cancer would decrease because any cancer would have been detected at an earlier stage.

The five types of cancers analyzed in this study have screening methods that allow for detection at an early stage, though in some instances, debate remains over efficacy and appropriate use: mammography for breast cancer, colonoscopy for colorectal cancer, Pap smear and / or HPV test for cervical cancer, spiral computed tomography or CT for lung cancer, and PSA test for prostate cancer.

But the early stage work is promising, he says, because it holds out hope that doctors will soon be able to image breast cancer with several techniques simultaneously, significantly increasing the chances of spotting the disease in its earliest stages.

Prior studies that examined the impact of cancer treatment decisions on employment showed that patients who received chemotherapy were most likely to experience longer disruptions in or loss of employment, but changes in breast cancer management in recent years have shifted recommendations away from chemotherapy for early stage breast cancer.

Women who pursue a more aggressive surgery for early stage breast cancer have nearly eight times the odds of reporting substantial employment disruptions, according to a new study from University of Michigan Comprehensive Cancer Center researcancer have nearly eight times the odds of reporting substantial employment disruptions, according to a new study from University of Michigan Comprehensive Cancer Center researCancer Center researchers.

Among women diagnosed with early - stage breast cancer in California, the percentage undergoing a double mastectomy increased substantially between 1998 and 2011, although this procedure was not associated with a lower risk of death than breast - conserving surgery plus radiation, according to a study in the September 3 issue of JAMA.

The findings provide the highest level of evidence supporting expert - derived clinical practice guidelines which have recommended Oncotype DX in patients with early stage ER - positive breast cancer.

«The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk - stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medcancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of MedCancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.

«These findings will give women with early stage breast cancer greater certainty that anti-estrogen therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,» said breast cancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates Commcancer greater certainty that anti-estrogen therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,» said breast cancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates Commcancer survivor Mary Lou Smith, JD, MBA, who helped design the study as a leader in the ECOG - ACRIN Cancer Research Advocates CommCancer Research Advocates Committee.

Initial results were announced from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,cancer sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,Cancer Institute (NCI), part of the National Institutes of Health, and led by the ECOG - ACRIN Cancer Research Group (ECOG - ACRIN) with support from Genomic Health,Cancer Research Group (ECOG - ACRIN) with support from Genomic Health, Inc..

The study, published in Cancer, surveyed 1,006 women who were treated for early stage breast cancer and were employed at the time of their diagCancer, surveyed 1,006 women who were treated for early stage breast cancer and were employed at the time of their diagcancer and were employed at the time of their diagnosis.

Since small, early - stage cancers are the most responsive to drug treatments, screening is an important aspect of follow - up care for breast cancer patients, and early detection is critical in tailoring appropriate and effective therapeutic interventions.

When factoring in what is now known about breast cancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer Ccancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer CCancer Center.

This shows promise for breast cancer patients as diagnosing and treating the breast cancer at early stages means there is a greater chance of preventing cancer cells spreading to other tissues, such as the lungs, brain and bone.

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

A new study finds that more than half of women with early stage breast cancer considered an aggressive type of surgery to remove both breasts.

African American women with early stage, invasive breast cancer were 12 percent less likely than Caucasian women with the same diagnosis to receive a minimally invasive technique, axillary sentinel lymph node (SLN) biopsy, even as the procedure had become the standard of surgical practice, according to research from The University of Texas MD Anderson Cancer Ccancer were 12 percent less likely than Caucasian women with the same diagnosis to receive a minimally invasive technique, axillary sentinel lymph node (SLN) biopsy, even as the procedure had become the standard of surgical practice, according to research from The University of Texas MD Anderson Cancer CCancer Center.

A considerably superior survival, both specific to breast cancer and from any cause of death, was found for BCT in the early stage T1 - 2N0 - 1M0 cancers in both time cohorts,» says Prof Siesling.

The growth rate of the cells exploded, and they quickly became disorganized masses characteristic of early stage, aggressive breast cancer, the team reports in the 7 February issue of the Journal of Experimental Medicine.

«A large majority of cancers present symptomatically, but symptoms may be subtle especially in the early stages in certain cancer types such as gastric, pancreatic or ovarian cancers, as opposed to say a more obvious palpable mass such as in breast cancer.»

Current guidelines for treating early - stage breast cancer — cancer that has not spread to nearby lymph nodes or other parts of the body — result in thousands of women receiving chemotherapy without benefitting from it.

Nuclear localization of KLF4 is associated with an aggressive phenotype in early - stage breast cancer

Breast cancer is becoming a curable disease when diagnosed at an early stage; however, the majority of cancer - related death is still attributed to metastatic disease.

It recognises the four most common types of cancer — prostate, lung, colon and breast cancer — at a very early stage, namely when the level of calcium in the blood is elevated due to the developing tumour.

«This study demonstrates that Prosigna can reliably identify early stage breast cancer patients who have a low risk - of disease recurrence at 10 years, including a substantial proportion of patients with node - positive disease for whom the risk / benefit derived for adjuvant chemotherapy would be at best neutral,» said Dr. Alessandra Cesano, chief medical officer of NanoString Technologies.

Letrozole is approved by the FDA for the adjuvant treatment of early - stage breast cancer in postmenopausal women who have already been treated with 5 years of tamoxifen therapy.

In an article published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodes.

«These results have driven us to update our treatment guidelines in Denmark to include testing with Prosigna as part of the workup of postmenopausal women with early stage HR - positive / Her -2 negative breast cancer, including patients with node - positive disease.»

Of the 1,551 women with early - stage breast cancer who were randomized to the comparison group of the WHEL study, more than half (864, or 56 percent) were taking tamoxifen, and more than three - quarters of those (674, or 78 percent) reported hot flasheOf the 1,551 women with early - stage breast cancer who were randomized to the comparison group of the WHEL study, more than half (864, or 56 percent) were taking tamoxifen, and more than three - quarters of those (674, or 78 percent) reported hot flasheof the WHEL study, more than half (864, or 56 percent) were taking tamoxifen, and more than three - quarters of those (674, or 78 percent) reported hot flasheof those (674, or 78 percent) reported hot flashes.

FDA approves trastuzumab (Herceptin) for use with other drugs in the adjuvant treatment of women with early - stage node - positive HER2 - overexpressing breast cancer.

FDA approves the aromatase inhibitors anastrozole and exemestane for the adjuvant treatment of hormone receptor - positive early - stage breast cancer.

The stages of cancer describe how advanced the cancer is Stage zero breast cancer is the earliest form of breast cancer, and the easiest to treat.

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andBreast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andbreast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

Though trastuzumab and pertuzumab have increased response rates and improved outcomes in HER2 - positive breast cancer, 30 % to 40 % of early - stage patients treated in the neoadjuvant setting will have residual disease at the time of surgery.

The authors built a statistical simulation model to estimate the 25 - year incremental costs per quality - adjusted life - year (QALY) for Oncotype DX testing in order to evaluate the cost - effectiveness of GEP testing among patients with early - stage ER - positive / HER2 - negative breast cancer treated in community oncology practices.